The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ...
TUCKER, Ga. & ROCKVILLE, Md.--(BUSINESS WIRE)--Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract ...
Results from the Children’s Oncology Group (COG) AML trials showed that benefit from GO at a single dose of 3 mg/m 2 at first induction and then intensification 9 was restricted to paediatric patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback